Presentation Material for

FY2021 Q2 Financial Results

Medley, Inc.

August 13, 2021

Disclaimer / Disclosure Policy

Disclaimer

In preparing these materials, Medley, Inc. ("the Company") relies upon and assumes the accuracy and completeness of all available information. This presentation may contain

future assumptions, prospects and forecasts based on planning, but these forward-looking statements are based on the information that is currently available to us, and on certain

assumptions that we assume to be reasonable, but the Company does not promise to achieve these. Major differences may occur between the forecast and the actual performance,

including changes in economic conditions, consumer needs and user preferences; competition with other companies; changes in laws, regulations and others; and a number of other

future factors. Therefore, the actual performance announced may vary depending on these various factors.

Disclosure Policy

The Company plans to disclose the latest information, including the status of progress, at the end of each fiscal year under the section of "Business Plan and Growth

Opportunities and Strategies". However, the Company's financial data and key performance indicators are planned to be disclosed at the end of each quarter.

Copyright© Medley, Inc . ALL RIGHTS RESERVED .

2

  1. Financial Highlights
  2. FY2021 Q2 Results
  3. FY2021 Forecast
  4. Appendix

3

Financial Highlights

FY2021 Q2

Results

  • Steady progress toward our earnings targets despite some impact from administration
    of COVID-19 vaccines by hospitals, clinics, and nursing homes
  • Maintained high sales growth rate and continued aggressive investment in growth
    • Sales：JPY 3,413 million (YoY: +47%)
    • EBITDA：JPY 1,110 million (YoY: +59%)(1)

FY2021

Forecast

  • Continue to make progress toward our medium- and long-term goals even as we
    face COVID-19
  • Leave our full-year FY2021 forecast unchanged while factoring in the impact of
    vaccinations
    • Sales：JPY 10,770~11,270 million (YoY: +58~65%)
    • EBITDA：JPY 670~1,170 million (EBITDA margin: 6~10%)(1)
  • Strengthen efforts to achieve our medium-term targets while responding to changes
    in the operating environment caused by COVID-19
    • Capital and business alliance with NTT DOCOMO, INC.

(1) Share-based compensation expenses are included in the calculation of EBITDA starting in FY2021. This change does not have any impact on EBITDA of FY2020 or before.

Copyright© Medley, Inc . ALL RIGHTS RESERVED .

4

  1. Financial Highlights
  2. FY2021 Q2 Results
  3. FY2021 Forecast
  4. Appendix

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Medley Inc. published this content on 13 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 August 2021 06:10:09 UTC.